Clinical Trials Logo

Cutaneous T-Cell Lymphoma clinical trials

View clinical trials related to Cutaneous T-Cell Lymphoma.

Filter by:

NCT ID: NCT01569724 Completed - Clinical trials for Hypertriglyceridemia

Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma

TgBEX
Start date: January 2012
Phase: Phase 4
Study type: Interventional

Bexarotene is a RXR-selective retinoid, licensed for the treatment of cutaneous T cell lymphoma. The most frequent adverse effect is hypertriglyceridemia but its mechanism is not well known. The purpose of this study is to research a carbohydrate metabolism disorder associated in bexarotene-induced hypertriglyceridemia.

NCT ID: NCT01556828 Terminated - Mycosis Fungoides Clinical Trials

Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing

Start date: June 2011
Phase: N/A
Study type: Observational

The goal of this study is to identify genetic changes associated with the initiation, progression, and treatment response of response of cutaneous and hematologic disorders using recently developed high-throughput sequencing technologies. The improved understanding of the genetic changes associated with cutaneous and hematologic disorders may lead to improved diagnostic, prognostic and therapeutic options for these disorders.

NCT ID: NCT01460914 Active, not recruiting - Clinical trials for Graft Versus Host Disease

Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment

Start date: October 2011
Phase:
Study type: Observational

Extracorporeal Photopheresis (ECP) is a form of apheresis and photodynamic therapy in which the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV light. ECP is currently a standard therapy for cutaneous T-cell lymphoma (CTCL) and is also effective for graft-versus-host disease (GVHD). The investigators would like to study the outcomes (response rates) of patients receiving ECP treatment and other factors relating to their disease and treatment, as well as procedural events, such as complications.

NCT ID: NCT01445340 Terminated - Neoplasms Clinical Trials

Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma

Start date: April 21, 2007
Phase: Phase 1
Study type: Interventional

Background: - Cutaneous T-cell lymphoma (CTCL) is a rare, slow-growing form of skin cancer. The cancer cells are found in red, scaly patches that may sometimes itch. - Early-stage CTCL is usually treated with topical therapies, which may lose effectiveness over time and have adverse effects, such as risk of secondary skin cancers and difficulty of use. - Romidepsin is an experimental drug that, given through a vein, has improved CTCL in some patients with later stages of the disease. - A topical ointment form of romidepsin may be helpful in treating early-stage CTCL. Objectives: - To determine the highest tolerated dose of topical romidepsin that can be given to patients with early-stage CTCL. - To evaluate the effectiveness of topical romidepsin in patients with early-stage CTCL. - To determine how the body handles topical romidepsin. Eligibility: -Patients 18 of age and older with early-stage CTCL. Design: - Study Part 1: Successive groups of 3 patients are treated with increasingly higher concentrations of topical romidepsin until the highest tolerated dose is found. - Study Part II: The highest tolerated dose, as determined in Part I, is applied to larger areas of skin in another group of patients. - All study participants apply the study medicine to their skin three times a day for 4 weeks. - During treatment, participants are monitored at weeks 2 and 4 with a history and physical examination, blood tests, electrocardiogram, skin biopsies and photographs of the skin. - After stopping treatment, participants return to the clinic at weeks 6 and 8 for blood tests and to see how the study medication is affecting the body.

NCT ID: NCT01396070 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level

Start date: June 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to learn the effects of an investigational medication, SGN 35, on patients with mycosis fungoides. Despite a wide range of therapeutic options, the treatments are associated with short response duration, thus this condition is largely incurable. This investigational drug may offer less toxicity than standard treatments and have better tumor specific targeting.

NCT ID: NCT01226472 Completed - Clinical trials for Peripheral T-cell Lymphoma

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in study, KW-0761-001.

NCT ID: NCT01198665 Completed - Clinical trials for Cutaneous T Cell Lymphoma

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

RADCHOP
Start date: July 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The urgent need for new effective therapy for T-cell lymphoma patients and promising results observed so far in trials with RAD001(everolimus, mTOR inhibitor) strongly warrants the investigation of RAD001 combined with CHOP as a first-line treatment in peripheral T-cell lymphoma patients. Thus, we designed a phase I/II study with the combination of RAD001 with CHOP chemotherapy for newly diagnosed peripheral T-cell lymphoma patients. Phase I 1. Primary objective : To define the maximum tolerable dose 2. Secondary objective - To evaluate the dose-limiting toxicity - To evaluate the pharmacokinetics of RAD001 - Pharmacogenomic profiling Phase II 1. Primary objective : To evaluate the overall response rate 2. Secondary objective - To estimate the time to progression - To estimate overall survival - Pharmacogenomic profiling

NCT ID: NCT01187446 Terminated - Clinical trials for Cutaneous T-cell Lymphoma

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over low-dose TSEBT alone in participants with mycosis fungoides (MF) Treatment in this study is TSEBT +/- vorinostat, with participants stratified by MF stage.

NCT ID: NCT01134341 Completed - Mycosis Fungoides Clinical Trials

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.

NCT ID: NCT01132989 Recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

REvMM2009
Start date: May 2010
Phase: Phase 2
Study type: Interventional

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be greater emphasis on combination treatment, which correlates with increased response rate, more rapid onset of response, and decreased side effect profile compared to monotherapy. The goal for the use of Lenalidomide as an adjuvant treatment in patients with refractory cutaneous T cell lymphoma is to increase response rates, maintain a durable long-term response, relieve associated symptoms, and minimize toxic side effects.